Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GALT NASDAQ:NCNA NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$3.92+25.6%$2.46$2.03▼$7.13$205.47M0.47449,969 shs2.05 million shsNCNANuCana$1.64-5.2%$2.04$1.33▼$25.58$7.20M2.1848,969 shs43,306 shsSPROSpero Therapeutics$2.10-2.3%$2.65$1.80▼$3.22$124.49M1.451.78 million shs887,736 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics+25.64%+41.52%+56.80%+40.00%+61.98%NCNANuCana-5.20%-11.83%-18.81%+10.81%-90.94%SPROSpero Therapeutics-2.33%-0.47%-23.91%-11.39%-27.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$3.92+25.6%$2.46$2.03▼$7.13$205.47M0.47449,969 shs2.05 million shsNCNANuCana$1.64-5.2%$2.04$1.33▼$25.58$7.20M2.1848,969 shs43,306 shsSPROSpero Therapeutics$2.10-2.3%$2.65$1.80▼$3.22$124.49M1.451.78 million shs887,736 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics+25.64%+41.52%+56.80%+40.00%+61.98%NCNANuCana-5.20%-11.83%-18.81%+10.81%-90.94%SPROSpero Therapeutics-2.33%-0.47%-23.91%-11.39%-27.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGALTGalectin Therapeutics 2.00Hold$11.00180.61% UpsideNCNANuCana 1.00SellN/AN/ASPROSpero Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest GALT, SPRO, and NCNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026GALTGalectin Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.006/18/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NCNANuCana Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SPROSpero Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/ANCNANuCanaN/AN/AN/AN/A$7.71 per shareN/ASPROSpero Therapeutics$66.80M1.82$0.15 per share14.13$1.05 per share2.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGALTGalectin Therapeutics-$30.84M-$0.41N/AN/AN/AN/AN/A-164.69%8/13/2026 (Estimated)NCNANuCana-$38.71M-$2.98N/AN/AN/AN/A-153.61%-116.03%8/13/2026 (Estimated)SPROSpero Therapeutics$8.57M$0.248.75N/AN/A24.90%35.58%24.95%8/11/2026 (Estimated)Latest GALT, SPRO, and NCNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026GALTGalectin Therapeutics-$0.06-$0.08-$0.02-$0.08N/AN/A5/15/2026Q1 2026NCNANuCana-$2.6440-$1.25+$1.3940N/AN/AN/A5/13/2026Q1 2026SPROSpero Therapeutics-$0.18-$0.13+$0.05-$0.13$0.26 million$0.26 million3/31/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/A3/26/2026Q4 2025SPROSpero Therapeutics-$0.20$0.53+$0.73$0.53$26.00 million$41.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGALTGalectin TherapeuticsN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGALTGalectin TherapeuticsN/A2.152.15NCNANuCanaN/A5.485.48SPROSpero TherapeuticsN/A10.5010.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGALTGalectin Therapeutics11.68%NCNANuCana44.00%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipGALTGalectin Therapeutics52.60%NCNANuCana31.20%SPROSpero Therapeutics2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGALTGalectin Therapeutics965.86 million31.22 millionOptionableNCNANuCana304.16 million2.86 millionNot OptionableSPROSpero Therapeutics15057.90 million56.22 millionOptionableGALT, SPRO, and NCNA HeadlinesRecent News About These CompaniesBiggest stock movers Thursday: INTC, KR, ACN, and moreJune 18, 2026 | seekingalpha.comSpero shares jump after FDA clears first oral carbapenem antibiotic for US market (SPRO)June 18, 2026 | msn.comGSK's Utebzi Wins FDA Nod for Complicated Urinary Tract InfectionsJune 18, 2026 | zacks.comSpero Therapeutics, Inc.: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 18, 2026 | finanznachrichten.deFDA approves first oral carbapenem therapy for cUTIsJune 17, 2026 | thepharmaletter.comTUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 17, 2026 | globenewswire.comSpero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)June 10, 2026 | seekingalpha.comSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateMay 13, 2026 | globenewswire.comEsther Rajavelu Sells 25,240 Shares of Spero Therapeutics (NASDAQ:SPRO) StockMay 7, 2026 | insidertrades.comSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026May 5, 2026 | globenewswire.comSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateMarch 26, 2026 | globenewswire.comSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026March 18, 2026 | globenewswire.comSpero Therapeutics: Tebipenem's FDA Path Supports A Speculative BuyFebruary 11, 2026 | seekingalpha.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $207,484.12 in StockFebruary 10, 2026 | insidertrades.comInsider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares of StockFebruary 6, 2026 | insidertrades.comWhy Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 7.48%February 4, 2026 | aaii.comAFormer Spero execs fined by SEC over antibiotic efficacy claimsJanuary 20, 2026 | fiercebiotech.comFSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisDecember 19, 2025 | globenewswire.comIs Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?December 15, 2025 | finance.yahoo.comSpero Therapeutics (SPRO) price target decreased by 20.00% to 4.08December 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGALT, SPRO, and NCNA Company DescriptionsGalectin Therapeutics NASDAQ:GALT$3.92 +0.80 (+25.64%) As of 06/24/2026 04:00 PM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.NuCana NASDAQ:NCNA$1.64 -0.09 (-5.20%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$1.67 +0.03 (+1.83%) As of 06/24/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Spero Therapeutics NASDAQ:SPRO$2.10 -0.05 (-2.33%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$2.15 +0.05 (+2.38%) As of 06/24/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
